AstraZeneca May Know COVID-19 Vaccine's Effectiveness by Year-End

Pascal Soriot, AstraZeneca's CEO, told an online briefing organized by Tortoise Media on September 10, 2020, that an independent safety committee was currently reviewing data on the AZD1222 vaccine candidates' reported adverse event. And the company should know before the end of 2020 whether this experimental vaccine protects people against the SARS-CoV-2 virus.

“Of course it depends on the outcome of this review... but if the safety committee allows us to restart the trial ... we are on track to have a set of data we can submit to regulators before the end of the year,” Soriot said.

Additional COVID-19 vaccine phase 3 studies are listed at CoronavirusToday.